

**UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION**

In the Matter of

SCHERING-PLOUGH CORPORATION,
a corporation,

UPSHER-SMITH LABORATORIES, INC.
a corporation,

and

AMERICAN HOME PRODUCTS

Docket No.: 9297

PLAINTIFF'S EXHIBIT LIST December 14, 2001

Exhibit No.	Document Description	Document No.	Source
	UPSHER IS A CORPORATION		
CX 1	“Upsher Articles of Incorporation”	Upsher-Smith-FTC-000001 - 000025	Upsher-Smith
	POTASSIUM CHLORIDE SUPPLEMENT		
CX 2	K-Dur 20 mEq Review	SP003042 - 003043	Schering-Plough
CX 3	Part I.		

Exhibit No.

CX 17

Document Description

Document No.

Source

Exhibit No.	Document Description	Document No.	Source
CX 29	Potassium File	Upsher-Smith-FTC-1001839 - 1001846	Upsher-Smith
CX 30	Klor-Con, Bulk & Private Label Tablets, 1/10/00, J. Adams, Rev. No.: 2000 Plan	Upsher-Smith-FTC-152954 - 152993	Upsher-Smith
CX 31	Klor-Con M Team Meeting Notes 1/12/00	Upsher-Smith-FTC-154612 - 154613	Upsher-Smith
CX 32			

Exhibit No.	Document Description	Document No.	Source
CX 43	National Prescription Audit Data -1996-2000, Potassium Chloride supplements	SP020658 - 020685	Schering-Plough
CX 44	Market 94-97 actual dollars plus current trend projections, dollars, tab/caps, units, s. Dolan	Upsher-Smith-FTC-191779 - 191786	Upsher-Smith
CX 45	<i>Data Lists</i> , "Retail Perspective and Provider Perspective, Non-Federal Hospitals, Combined Purchases,"; Vol. 3; IMS America, 1/1997 - 12/1997.	ABT000031 - 000044	Abbott
CX 46	<i>Data Lists</i> , "Retail Perspective and Provider Perspective Non-Federal Hospitals, Combined Purchases, Reissue March 2000", Vol. 3; 1/1999 - 12/1999.	ABT000045 - 000055	Abbott
CX 47	IMS 1997-98, dollar, unit sales potassium chloride supplements	USL07428	Upsher-Smith
CX 48	Jan. - Sept. Plan vs Actuals 1999 (Sales)	USL18755 - 18761	Upsher-Smith
CX 49	Price Increase History for NDC: 00085-0263-01, K-Dur 10,20; 1995-2000	SP049048 - 049053	Schering-Plough
CX 50	New Business Opportunities Klor-Con Tablets, April 1999, Market info, costs, competition	USL13473 - 13530	Upsher-Smith
CX 51	Memo re potassium supplement pricing, 7/29/99, No.: 521.007; Marketing Scenario to U-S Sales Department	Upsher-Smith-FTC-195767 - 195770	Upsher-Smith
CX 52	Correspondence to Douglas Sporn, FDA from Jacqueline Davis, Andrx re Original Abbreviated New Drug Application for potassium chloride extended-release tablets USP, 10 mEq & 20 mEq, 3/22/99	ANDX-SP005046	Andrx
CX 53	Patent Certification Under 21 CFR §314.94 and Notice of Certification of Invalidity or Noninfringement of a Patent Under 21 CFR §314.95 (Andrx)	SP21 00004 - 00022	Schering-Plough
CX 54	E-mail re KCL Forecast, 9/22/99, Cohen to Cobb	ANDX-SP001158	Andrx

Exhibit No.	Document Description	Document No.	Source
CX 55	2002 Preferred Drug List, United Healthcare	FTC0022170 - 0022200	United Healthcare
CX 56	Rx Selections Formulary	MERCK-MEDCO000193 - 000198	MERCK-MEDCO
CX 57	Preferred Prescriptions Formulary	MERCK-MEDCO000187 - 000192	MERCK-MEDCO
CX 58	Potassium Supplement (8 MEQ Strength) P&T Therapeutic Interchange Proposal	MERCK-MEDCO000153 - 000159	MERCK-MEDCO
CX 59	Correspondence to Mark Halvorsen, US from Douglas Sporn, FDA, approving ANDA for Klor-Con 20, 11/20/98	Upsher-Smith-FTC-087345 - 087346	Upsher-Smith
CX 60	Memo from Pickett to Baldini and Driscoll re K-DUR long term strategy, 3/8/95	SP076520 - 076524	Schering-Plough
CX 61	K-DUR Generic strategy status report/action plan	SP076525 - 076527	Schering-Plough
CX 62	Potassium Chloride Market Monthly Rx Report NRX, 12/97	SP089324 - 089327	Schering-Plough
CX 63	Potassium Chloride Market Monthly Rx Report NRX, 12/98	SP089328 - 089331	Schering-Plough
CX 64	Potassium Chloride Market Monthly Rx Report NRX, 12/99	SP089332 - 089335	Schering-Plough
CX 65	Potassium Chloride Market Monthly Rx Report NRX	SP089336 - 089339	Schering-Plough
CX 66	Direct Price List, 6/99	Upsher-Smith-FTC-1030413 - 1030414	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 67	Executive Summary, Sales Plan, Klor-Con M20, 3/22/01 Draft	Upsher-Smith-FTC-137991 - 138027	Upsher-Smith
CX 68	American Home Products Corporation, Annual Report, 1999	FTC0020194 - 0020278	AHP
CX 69	M10/M20 Market Data, 2/15/00	Upsher-Smith-FTC-142724 - 142771	Upsher-Smith
CX 70	Forecast team, Performance, Marketing views, Weekly Sales Summary, 7/01	Upsher-Smith-FTC-141772 - 142233	Upsher-Smith
CX 71	“Perspective Report”, 10/15/97	Upsher-Smith-FTC-142234 - 142325	Upsher-Smith
CX 72	Klor-Con Market Data 1 of 3	Upsher-Smith-FTC-142532 - 142723	Upsher-Smith
CX 73	December 2000 In Line	Upsher-Smith-FTC-143200 - 143298	Upsher-Smith
CX 74	M10/M20 Market Data, 2/15/00	Upsher-Smith-FTC- 142724 - 142771	Upsher-Smith
CX 75	Marie Von Ende, Klor-Con Market Data, 2000, 2001	Upsher-Smith-FTC-142326 - 142404	Upsher-Smith
CX 76	Klor-Con 8 & 10 Potassium Chloride Extended Release Tabs, USP, Private Label 8 & 10mEq Tabs, 1/00	Upsher-Smith-FTC- 162109 - 162111	Upsher-Smith
CX 77	Potassium Market Conditions	Upsher-Smith-FTC- 163552 - 163553	Upsher-Smith
CX 78	E-mail to John Adams from Chris Evenstad re K-Dur Price Increases 8/99-8/00, 8/16/00, forwarded to Terri Johnson 8/19/01	Upsher-Smith-FTC- 1025661	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 79	Potassium Cumulative Market Projection	Upsher-Smith-FTC- 138065 - 138066	Upsher-Smith
CX 80	E-mail from Annamarie Lee to Sherry Dann re Potassium Pharmacy Data, 7/11/01	Upsher-Smith-FTC- 1026013	Upsher-Smith
CX 81	Potassium Chloride Market, New Products Prescriptions (000), 12/94 through 12/95	SP089318 - 089320	Schering-Plough
CX 82	Potassium Chloride Market, New Products Prescriptions (000), 12/95 through 12/96	SP089321 - 089323	Schering-Plough
CX 83	Upsher's IMS Physician Exponent Data by Month/Rep, K-Dur 20, Sorted by ASR, Unit Data Only, All Physicians, 9/00 through 8/01	Upsher-Smith-FTC- 1034802 - 1034923	Upsher-Smith
CX 84-113	RESERVED		
FORECASTS			
CX 114	Upsher-Smith 1997 Sales Plan, 1997 Actuals and forecast, revised, 5/97, J. Hughes	USL13151 - 13152	Upsher-Smith
CX 115	Five Year K-DUR Sales Forecast, 8/30/95; Birch to Monroe	SP004794 - 004799	Schering-Plough
CX 116	Schering Labs, 1995 Operating Plan Data Perspective, \$ Millions, 11/10/94	SP23 000216	Schering-Plough
CX 117	Schering Labs, 1996 Operating Plan Data Perspective \$Millions, 11/14/95	SP23 00021 - 00217a	Schering-Plough
CX 118	Schering Labs, Sales by major product classification, 1997 Operating Plan, \$ Thousands, 11/11/96	SP23 00218aa - 00219aa	Schering-Plough
CX 119	Schering Labs, Sales by major product classification, 1999 Operating Plan, \$ Thousands	SP23 00220a	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 120	Schering Labs, Five year sales forecast by product	SP23 00297a	Schering-Plough
CX 121	Schering Labs, Five year forecast (1997-2001) Assumptions	SP23 00299a - 00303a	Schering-Plough
CX 122	Voluntary recall of K-Dur 20 S.R. Tablets, lot #94167, Forecasts 2001-2002, 6/5/97	SP23 00292 - 00334	Schering-Plough
CX 123	1996 Key Pharmaceuticals, K-DR 5 Year Unit Projection, Assumption: No Generics		

Exhibit No.	Document Description	Document No.	Source
CX 132	1997 K-DUR Forecast	SP23 00213	Schering-Plough
CX 133	Key Pharmaceuticals, 1997 Operating Plan, K-DUR Generic Module, Lindquist to Inserra, 3/2/97	SP25 00004 - 00005	Schering-Plough
CX 134	K-DUR Base Case Financial Analysis, 6/28/98, with and with out Lozenge	SP004672 - 004704	Schering-Plough
CX 135	K-Dur Lozenge (K-dur/Rebetol), 8/22/98, spread sheet	SP23 00344 - 00356	Schering-Plough
CX 136	Schering 1995 Operating Plan Data Perspective	SP23 00216	Schering-Plough
CX 137	<i>Product Forecast</i> , K-Dur: 1996 sales plan, 1997-2000 forecasts; 1996.	SP23 00325	Schering-Plough
CX 138	Klor-Con M20 Sept Launch with Private Label and Warrick (Units)	Upsher-Smith-FTC-0000788 - 0000790	Upsher-Smith
CX 139	Strategic Business Objectives	SP23 00215	Schering-Plough
CX 140	K-DUR: For the treatment and prevention of hypokalemia	SP23 00001 - 00009	Schering-Plough
CX 141	<i>Forecasts from files of Lawrence Alaburda</i> , "Key Pharmaceuticals, K-Dur Generic Sales Impact Summary - non-infringement, \$(000)'s"; <i>provided by Key</i> , date unclear.	501 DOC000647	AHP
CX 142	Correspondence re Warrick Contingency Plan for Potassium Chloride ER Tablets, 2/26/97	SP25 00001 - 00058	Schering-Plough
CX 143	Handwritten Note with attached correspondence re Warrick Contingency Plan for Potassium Chloride ER Tablets, 2/26/97	SP26 00001 - 00008	Schering-Plough
CX 144	Standard Costs K-DUR: Potassium Chloride Tablets Warrick 12 month forecast	SP22 00001 - 00005	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 145	Warrick Five Year Forecast Feb. 1996 Assumptions: K-DUR generic launch 7/97	SP23 00335 - 00339	Schering-Plough
CX 146	Long term Planning new Product Profitability Statement 4/2/96	USL05751 - 05753	Upsher-Smith
CX 147	Long Term Planning Meeting 9/11/96	USL12744 - 12772	Upsher-Smith
CX 148	Memo re Monthly Report, 3/5/97	Upsher-Smith-FTC-153540	Upsher-Smith
CX 149	20 MEQ KCL Market, D. Dolan, 4/15/97	USL06733	Upsher-Smith
CX 150	20 mEq Projection notes, Dolan, 5/97	USL08535 - 08539	Upsher-Smith
CX 151	Draft Long Term Plan 1999 to 2004	Upsher-Smith-FTC-1002630 - 1002656	Upsher-Smith
CX 152	Long Term Plan 1999 to 2004	USL08064 - 08085	Upsher-Smith
CX 153	Long Term Quantifiable Objectives (2001)	Upsher-Smith-FTC-172401 - 172522	Upsher-Smith
CX 154	E-Mail re Schering-Key-Warrick	Upsher-Smith-FTC-152404 - 152405	Upsher-Smith
CX 155			

Exhibit No.	Document Description	Document No.	Source
CX 157	Gen 3-KDUR, USL, Warrick, Pl	Upsher-Smith-FTC-151787 - 151796	Upsher-Smith
CX 158	Brand 1-KDUR, USL-Conserv SHR	Upsher-Smith-FTC-151809 - 151817	Upsher-Smith
CX 159	Brand with Warrick and PL	Upsher-Smith-FTC-151825 - 151827	Upsher-Smith
CX 160	1999 Scenario	Upsher-Smith-FTC-151998 - 152003	Upsher-Smith
CX 161	M20 Scenario Summary	USL08302	Upsher-Smith
CX 162	10 MEQ Microdispersable	USL06732	Upsher-Smith
CX 163	E-mail re Qualitest Klor-Con M Pricing	Upsher-Smith-FTC-1009883 - 1009884	Upsher-Smith
CX 164	Potassium chloride (20 mEq) Tablet Market Forecast	AHP13 00107 - 00125	AHP
CX 165	Letter re Potassium Chloride 20 mEq, 11/10/96	AHP13 00128 - 00129	AHP
CX 166	Potassium Chloride 20 mEq (K-DUR) Forecast 10/9/94	AHP13 00130	AHP
CX 167	Forecasts and attached memo, "subject: 20mEq Potassium Chloride Tablet forecast," from 1997-2001, to John Dagnello from Shafi Rahman, 1/10/97	AHP13 00104	
CX 168	20mEq Potassium Chloride Tablet forecast	AHP13 00106 - 00114	AHP
CX 169	K-DUR Analysis, 9/3/97, Multiple scenarios for generic entry	AHP13 00158 - 00184	AHP
CX 170	<i>Status report: pharmaceutical products</i> ; "Launch Year 1998", development remarks and comments on KCL 20 mEq; 12/4/97.	101 DOC001239 - 001243	AHP

Exhibit No.	Document Description	Document No.	Source
CX 171	M20 Development File	Upsher-Smith-FTC-138932 - 139004	Upsher-Smith
CX 172	Launch Forecast, 3/23/01	Upsher-Smith-FTC-138067 - 138084	Upsher-Smith
CX 173	Klor-Con M Market Estimates, 3/29/01	Upsher-Smith-FTC-138085	Upsher-Smith
CX 174	2001, MIC-CLEAR; Securities and Exchange Commission Form 10-K Annual Report	FTC0022249 - 0022320	FTC
CX 175	May 2001 Inline	Upsher-Smith-FTC-142822 - 142829	Upsher-Smith
CX 176	Klor-Con M, 8/8/00	Upsher-Smith-FTC-088249 - 088251	Upsher-Smith
CX 177	E-mail to Mark Evenstad from Mike McBride re K-DUR price analysis, 6/13/01	Upsher-Smith-FTC- 1026321 - 1026322	Upsher-Smith
CX 178	Monthly Upsher Sales Reports, Forecasts, and Historical, 11/97 thru 7/01	Upsher-Smith-FTC- 141772 - 142233	Upsher-Smith
CX 179	E-mail to John Lund from Marie Von Ende re Rolling Forecast, 8/15/01	Upsher-Smith-FTC- 1023729 - 1023736	Upsher-Smith
CX 180	E-mail to Robert Coleman from John Adams re M20 Pricing, 4/15/01	Upsher-Smith-FTC- 1025473 - 1025477	Upsher-Smith
CX 181	E-mail to Mike McBride from John Adams re M20 April 2001 Pricing Scenarios, 4/13/01	Upsher-Smith-FTC- 1025484 - 1025488	Upsher-Smith
CX 182	E-mail to Mike McBride from John Adams re M20 Pricing, Price Workbook, 2/16/01	Upsher-Smith-FTC- 1025489 - 1025490	Upsher-Smith
CX 183	E-mail to Jim Tempesta from John Adams re M20 Stuff, 20 mEq and 10 mEq, 1/22/01	Upsher-Smith-FTC- 1025578 - 1025580	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 184	E-mail to Mike McBride from John Adams re KC M20/M10 Pricing, 11/21/00	Upsher-Smith-FTC- 1025619 - 1025621	Upsher-Smith
CX 185	E-mails re 2001 Sales Plan in \$(000's) and units, 10/4/00 and 10/23/00	Upsher-Smith-FTC- 1025642 - 1025649	Upsher-Smith
CX 186	Upsher-Smith Labs, Klor-Con M, 8/8/00	Upsher-Smith-FTC- 155814 - 155817	Upsher-Smith
CX 187	Executive Summary, Sales Plan, Klor-Con M20 2001	Upsher-Smith-FTC- 137991 - 138027	Upsher-Smith
CX 188	Klor-Con M total tablets	Upsher-Smith-FTC- 138045 - 138050	Upsher-Smith
CX 189	Klor-Con M20 & M10 Launch Forecasts, Sales-National Accounts, 3/23/01, Sales Plan Totals	Upsher-Smith-FTC- 138067 - 138084	Upsher-Smith
CX 190	Kor-Con M20 Development File	Upsher-Smith-FTC- 138932 - 139004	Upsher-Smith
CX 191	E-mail to Mark Evenstad from John Adams re Klor-Con M20/M10 NPV, 8/30/00	Upsher-Smith-FTC- 1026472 - 1026475	Upsher-Smith
CX 192	E-mail to Nancy Wolter from John Adams re Klor-Con M20/M10 Units, 8/30/00	Upsher-Smith-FTC- 1026476 - 1026481	Upsher-Smith
CX 193	E-mail to Mark Evenstad from Marie Von Ende re M10/M20 Units & Extended Units, 8/10/00	Upsher-Smith-FTC- 1026526 - 1026527	Upsher-Smith
CX 194-223	RESERVED		
SCHERING/UPSHER-SMITH PATENT LITIGATION			
CX 224	What's the Title	SP25 00032 - 00047	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 225	Complaint filed 12/15/95 by Key Pharm. against Upsher-Smith	SP08 - 00002 - 00034	Schering-Plough
CX 226	Answer (to complaint, 12/15/95) filed 1/29/96 by Upsher-Smith	SP08 00035 - 00044	Schering-Plough
CX 227	Correspondence from Paul Kravlovec to Richard Larson re updated info with regard to ongoing litigation Upsher-Smith is involved with., 6/4/96	USL02876 - 02877	Upsher-Smith
CX 228	Upsher-Smith's memo in opposition to Key Pharm. motion to dismiss, filed 8/15/96	SP08 00224 - 00256	Schering-Plough
CX 229	Reply brief in support of Upsher-Smith's motion to strike certain of Key Pharm's affirmative defenses, 8/22/96	SP08 00257 - 00274	Schering-Plough
CX 230	Memo in support of Upsher-Smith's motion for summary judgement of non-infringement, 10/96	SP08 00372 - 00414	Schering-Plough
CX 231	Reply memo in support of Upsher-Smith's motion for summary judgement of non-infringement, hearing date 3/10/97	SP08 00454 - 00479	Schering-Plough
CX 232	Memo re monthly reports - operational committee, 2/6/97	USL15389 - 15399	Upsher-Smith
CX 233	Memo re Klor-Con M Tentative Approval, 3/12/97	USL13147	Upsher-Smith
CX 234	Memo re 1997-1999 long term plan, 10/9/96	USL12781 - 12808	Upsher-Smith
CX 235	Memo re Klor-Con M tentative approval, 5/13/97	USL06745	Upsher-Smith
CX 236	Reply of key Pharmaceuticals to Upsher's counterclaims, 2/20/96	ESI00597 - 00601 601 DOC000431 - 000435	AHP/ESI
CX 237	Declaration accompanying opposition of Key Pharmaceuticals' to Upsher-Smith's motion for summary judgement of non-infringement, Key v. Upsher-Smith, 1/7/97	USL PLD002760 - 002876	Upsher-Smith

Exhibit No.

Exhibit No.	Document Description	Document No.	Source
NEGOTIATIONS SCHERING/UPSHER-SMITH			
CX 295	Correspondence re abbreviated new drug application dated 8/8/95, 3/6/97	USL06727 - 06729	Upsher-Smith
CX 296T0 112	TD Tj -627.n912 Tc -03787 Tw (Correspondenfrom Kapur to Troupnce ScUpsing (Key Pharmaceutpplls) -w (Ups agreeocum,er-) Tj 0 -12 TD -85.091 Tc 0 T6/173/6/97) Tj 39		

r-) Tj 0 -12 TD -0.1605 Tc (Smith) Tj -627.75 -19.5 TD -0.3835 Tc 0.196 Tw (30 295) Tj 60.75 0 Tc -248912 Tc 1j -365 Tw pense Report/97) Tj 391.5 0 TD -3.0293 Tc 518c 0 TwP0 -00393727 04 1729) Tj 175.5

Exhibit No.	Document Description	Document No.	Source
CX 307	Expense Report	SP12 00388 - 00392	Schering-Plough
CX 308	Expense Report	SP12 00335 - 00337	Schering-Plough
CX 309	Ian Troup Desk calendar	Upsher-Smith-FTC-194131 - 194247	Upsher-Smith
CX 310	Schering draft of confidentiality agreement for disclosures re Niacor, Wasserstein to Troup, 6/10/97	SP16 00231 - 00235	Schering-Plough
CX 311	Settlement discussions	SP12 00111 - 00112	Schering-Plough
CX 312	License Terms for U-S Products, discussions	SP12 00001	Schering-Plough
CX 313	Points of Agreement with Key Pharmaceuticals., 6/17/97	SP12 00238 - 00243	Schering-Plough
CX 314	Points of Agreement with Key Pharmaceuticals., 6/17/97	SP12 00143 - 00148	Schering-Plough
CX 315	Upsher-Smith Financials 1995-1997	USL01223 - 01236	Upsher-Smith
CX 316	Income Statement, July Results	USL00964 - 01001	Upsher-Smith
CX 317	Financial Statements 1/3/99 and 1/4/98	USL01636 - 01652	Upsher-Smith
CX 318	K-DUR Lozenge/Nitro-DUR Color Change Quantitative Assessment	SP002659 - 002665	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 319	Memo re K-DUR 20 Meltab, 5/4/99	SP004709 - 004732	Schering-Plough
CX 320	Memo re K-DUR Meltab, 6/22/99	SP004738 - 004743	Schering-Plough
CX 321	Product Strategies, 4/2/96	USL05245 - 05248	Upsher-Smith
CX 322	Product Strategies, 9/11/96	USL05283 - 05288	Upsher-Smith
CX 323-337	RESERVED		
BOARD APPROVAL			
CX 338	<i>Presentation, forecasts and attached Internal Memorandum, "RE: Board of Director's Meeting- June 24, 1997", summary of proposed license agreement with Upsher-Smith; to Schering Board of Directors; from William Silbey; 6/19/97.</i>	SP12 00266 - 00275	Schering-Plough
CX 339	Board of Directors Presentation, Upsher-Smith Transactions	SP12 00254 - 00265	Schering-Plough
CX 340	Schering-Plough Corp's Meeting of the Board of Directors, 6/24/97	SP07 00001 - 00018	Schering-Plough
CX 341	Board of Director's Presentation, Upsher-Smith License, 6/24/97	SP12 00244 - 00253	Schering-Plough
CX 342-346	RESERVED		
SCHERING/UPSHER-SMITH AGREEMENT			
CX 347	Correspondence from Kapur to Troup re Schering (Key Pharmaceuticals) -Upsher agreement, 6/17/97	SP12 00189 - 00199	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 348	Settlement and License Agreement, 6/17/97	USL03183 - 03193	Upsher-Smith
CX 349-363	RESERVED		
POST AGREEMENT STAND DOWN			
CX 364	Klor-Con M20 , 7/97	USL12832 - 12838	Upsher-Smith
CX 365	Correspondence from Troup to Kapur re response to the status of launching the M20 product, 8/4/97	USL02061 - 02062	Upsher-Smith
CX 366	Audibert letter to Gorske requesting list of investigators, 8/21/97	SP05 00024	Schering-Plough
CX 367	Kapur to Troupe letter requesting group visit to plant for chlestyramine, mentions other products Upsher could produce, 7/16/97	SP05 00022 - 00023	Schering-Plough
CX 368-387	RESERVED		
UPSHER'S ABILITY TO LAUNCH			
CX 388	Klor-Con M20 Approval dates	USL16335 - 16341	Upsher-Smith
CX 389	Scale-Up Questions	Upsher-Smith-FTC-088079 - 088082	Upsher-Smith
CX 390	Klor Con M Team Meeting, 9/8/99	Upsher-Smith-FTC-088490 - 088491	Upsher-Smith
CX 391	E-mail re M20 Launch Quantities, 9/15/99	USL08250 - 08251	Upsher-Smith
CX 392	E-mail to Robert Coleman from John Adams re Klor-Con M20 Info, 1/5/99	Upsher-Smith-FTC- 1025786 - 1025787	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 393	Forecasts 9/20/99	Upsher-Smith-FTC-170084 - 170085	Upsher-Smith
CX 394	Follow-Up for IPC Meeting, 10/14/99	Upsher-Smith-FTC-170050 - 170060	Upsher-Smith
CX 395	Year 2001 - Total Tablets - 207,000,000	Upsher-Smith-FTC-170086 - 170124	Upsher-Smith
CX 396	Memo re Scientific affairs May Monthly Report, 5/3/00	Upsher-Smith-FTC-171911 - 171912	Upsher-Smith
CX 397-416	RESERVED		
ESI PATENT LITIGATION			
CX 417	<i>Letter and attached amended certification</i> , Subject: ESI's amended certification, under section 505 (J) (2) (A) (vii) (IV) and 21 CFR § 314.94, concerning the '743 patent; to Harris Weinstein (Covington & Burling, also submitted to the FDA); from Deborah Somerville (Kenyon & Kenyon); 5/6/96.	501 DOC002713 - 002714	AHP
ESI PATENT LITIGATION CONTINUED			
CX 418	<i>Letter</i> , "Re: Notice under section 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act - U.S. Patent 4,863,743"; to James Nelson (Schering-Plough Counsel, VP Patents and Trademarks); from Robert Wiser (ESI-Lederle Chief Patent Counsel); 1/22/96.	115 DOC000161 - 000163	AHP
CX 419			

Exhibit No.	Document Description	Document No.	Source
CX 422	Letter re Amended notice to patent holder and holder of approved drug pursuant to Section		

Exhibit No.	Document Description	Document No.	Source
CX 446-455	RESERVED		
ESI AGREEMENT AND NEGOTIATIONS			
CX 456	Letter re Key Pharmaceuticals v. ESI-Lederle, Inc., 12/6/96	AHP10 01079	AHP
CX 457	Letter re ESI has no sales force, 2/20/97	C+B-2 002175 - 002177	Covington & Burling
CX 458	Letter re ESI concerns about settlement proposal raising anti-trust risks, 3/19/97	C+B-2 002179	Covington & Burling
CX 459	<i>Letter, Key Pharmaceuticals v. ESI-Lederle, Inc. No. 96-CV-1219</i> , Subject: Settlement; to Judge Reuter (E.D. Pa); from Anthony Herman (Covington & Burling), 4/18/97.	AHP05 00190 - 00191	AHP
CX 460	Handwritten note, 9/26	SP13 00001	Schering-Plough
CX461	ESI projections of Potassium Chloride Sales, 9/97	SP13 00002 - 00004	Schering-Plough
CX 462	Letter re Key Pharmaceuticals v. ESI-Lederle, Inc., 7/25/97	AHP10 01670 - 01671	AHP
CX 463	Letter re Key Pharmaceuticals v. ESI-Lederle, Inc., 9/9/97	SP06 00039 - 00043	Schering-Plough
ESI AGREEMENT AND NEGOTIATIONS CONTINUED			
CX 464	<i>Letter and attached summary</i> , “Key Pharmaceuticals, Inc. v. ESI-Lederle, Inc. C.A. No. 96-1219 (E.D.Pa.)”, summary agreement; to Paul Heller (Kenyon & Kenyon); from Anthony Herman (Covington & Burling); 9/12/97.	501 DOC002989 - 002993	AHP
CX 465	Letter re interest for new generic products in the European market, 10/14/97		

Exhibit No.	Document Description	Document No.	Source
CX 466	Letter Dey to Driscoll: ESI wants to sell Key 20mEq tablet for a fee, 2/20/97	SP06 00030 - 00031	Schering-Plough
CX 467	<i>E-mail</i> , "subject: KCL FDA communication"; to Nick Tantillo; from Michael Dey; 11/11/97.	203 DOC000050	AHP
CX 468	<i>Letter</i> , Key Pharmaceuticals v. ESI-Lederle, Inc. No. 96-CV-1219 , Subject: Settlement Conference; to Judge Reuter (E.D. Pa); from Anthony Herman (Covington & Burling), 11/12/97.	AHP05 00225 - 00226	AHP
CX 469	<i>Letter and attached summary</i> , Key Pharmaceuticals v. ESI-Lederle, Inc. No. 96-CV-1219 , Subject: ANDA correspondence between ESI and FDA; to Paul Heller and Deborah Somerville (Kenyon & Kenyon); from Anthony Herman (Covington & Burling); 12/15/97.	AHP05 00175 - 00178	AHP
CX 470	Letter re Key Pharmaceuticals v. ESI-Lederle, Inc., 12/17/97	C+B-2 000003 - 000004	Covington & Burling
CX 471	Correspondence re Proposed settlement between Schering and ESI	SP06 00044 - 00050	Schering-Plough
CX 472	Handwritten notes	C+B-2 002196 -002197	Covington & Burling
CX 473	<i>Letter</i> , Key Pharmaceuticals v. ESI-Lederle, Inc. No. 96-CV-1219 , Subject: 12/22/97, Settlement proposal, 12/22/97; to Anthony Herman (Covington & Burling); from Paul Heller (Kenyon & Kenyon), 12/22/97.	AHP05 00239 - 00240	AHP
CX474	Berman letter to Somerville rejecting ESI changes to agreement, 6/17/98	SP13 00632 - 00635	Schering-Plough
ESI AGREEMENT AND NEGOTIATIONS CONTINUED			
CX 475	Letter re Key Pharmaceuticals v. ESI-Lederle, Inc., 1/26/98	C+B-2 000006	Covington & Burling

Exhibit No.	Document Description	Document No.	Source
CX 476	Presentation; Licensing Agreement between SPOC and Warrick, 2/25/98	SP13 00859 - 00866	Schering-Plough
CX 477	Minutes of Meeting 2/1998	SP07 00019 - 00022	Schering-Plough
CX 478	<i>Letter and attached settlement agreement, re: Key Pharmaceuticals v. ESI-Lederle, Inc. No. 96-CV-1219, to Paul Berman (Covington & Burling); from Deborah Somerville (Kenyon & Kenyon), 2/9/98.</i>	AHP05 00247 - 00260	AHP
CX 479	Settlement Agreement, 6/19/98	SP13 00070 - 00089	Schering-Plough
CX 480	License Agreement	SP15 00053 - 00152	Schering-Plough
CX 481	Letter re Notice of ANDA approval letter; settlement agreement dated 6/19/98 between Key, Schering, ESI and AHP, 5/12/99	SP13 00636 - 00661	Schering-Plough
CX 482	Letter re Settlement agreement, Key v. ESI; Generic K-DUR KC1 Tablets 20 meq, 5/12/99	SP13 00794 - 00820	Schering-Plough
CX 483	<i>Letter, Subject: settlement discussions between Schering and AHP, "Re: Key Pharmaceuticals Inc v. ESI Lederle, Inc., Civil Action No. 96-CV-1219"; 6/18/98.</i>	501 DOC002692 - 002693	AHP
CX 484	<i>Settlement Agreement, re: Key Pharmaceuticals v. ESI-Lederle, Inc. No. 96-CV-1219; Signed by Richard Zahn and Egon Berg (AHP); 6/19/98.</i>	AHP05 00052 - 00071	AHP
CX 485	<i>License Agreement; Contract between Key and ESI, concerning Enalapril and Buspirone ANDA etc...; signed by David Poorvin and Egon Berg; fax date- 6/19/98.</i>	AHP05 00074 - 00171	AHP
486ESI AGREEMENT AND NEGOTIATIONS CONTINUED			
CX 486	<i>Letters and attached settlement agreement, "Re: Notice of ANDA Approval Letter, Settlement agreement dated June 19, 1998 between Key... and AHP...", request for payment by AHP to Key; to various employees of Schering; from Lawrence Alaburda, 6/12/99.</i>	501 DOC004034 - 004066	AHP

Exhibit No.	Document Description	Document No.	Source
CX 512	<i>Letter and Data Tables</i> , Subject: possible co-promotion of Niaspan- attached sales activity summary and prescription data charts; to James Egan (Searle); from Mukesh Patel (Kos); 1/20/98.	AAA0000016 - 0000019	KOS
CX 513	<i>Notes of Conference Call</i> , Subject: pursuit of Niaspan business venture by Kos and Smith-Kline Beecham, "Outstanding Technical & Commercial Review Matters"; 11/6/97.	AAA0000010	KOS
CX 514	<i>Letter</i> , Subject: "feedback on Nicostatin", possible co-promotion of Niaspan; to Mukesh Patel (Kos); from Riccardo Carbucicchio (Knoll AG), 7/13/99.	AAA0000027 - 0000028	KOS
CX 515	<i>Letter</i> , Subject: interest in pursuit of Niaspan business venture; to Mukesh Patel (Kos); from Alain Benoit (Pierre-Fabre), 10/28/98.	AAA0000029	KOS
CX 516	<i>Letter</i> , Subject: follow-up on Niaspan; to Valerie Magre (Pierre-Fabre); from Mukesh Patel (Kos), 3/3/99.	AAA0000033	KOS
CX 517	<i>Financial proposal</i> , "Kos Pharmaceuticals, Inc., Nicostatin Co-Promotion Proposal to Roche"; 4/4/00.	AAA0000034 - 0000036	KOS
CX 518	<i>Internal Memo</i> , Subject: Schering interest in Niaspan business venture with Kos; to Dan Bell (Kos); from Mukesh Patel (Kos); 1/7/97.	AAA0000037	KOS
CX 519	<i>Letter</i> , returned attachment of signed Niaspan CDA from Schering to Kos; to Mukesh Patel (Kos); from Karin Gast; 1/31/97.	AAA0000048 - 0000051	KOS
CX 520	Phone call to Karin Gast from Mukesh Patel re interest in Niaspan, availability of Niaspan, 1/15/97	SPCID2 1A 00092	Schering-Plough
CX 521	Niaspan	Pharmacia0000045 FTC0005112	Pharmacia
CX 522	Memo re KOS Pharmaceuticals, 10/6/97	Pharmacia0000041 - 0000043 FTC0005108 - 0005110	Pharmacia
KOS CONTINUED			
CX 523	E-mail re KOS Niaspan, 11/3/97	Pharmacia0000040 FTC0005107	Pharmacia

Exhibit No.	Document Description	Document No.	Source
CX 524	E-mail re KOS Niaspan, 11/11/97	Pharmacia0000036 - 0000039 FTC0005103 - 0005106	Pharmacia
CX 525	Letter re Meeting on Niaspan 12/7/97, 1/20/98	Pharmacia0000031 - 0000035 FTC0005098 - 005102	Pharmacia
CX 526	Memo re KOS Niaspan	Pharmacia0000002 - 0000030 FTC0005070 - 0005097	Pharmacia
CX 527	<i>Licensing summary</i> , Niaspan License in Territories Outside North America, Kos/Astra; 5/18/98.	AAA0000171	KOS
CX 528	<i>Letter</i> , Subject: decision not to pursue Niaspan business venture; from B.J. Jordan (Synthelabo); to Mukesh Patel (Kos); 2/24/98 and 10/24/97.	AAA0000161 - 0000162	KOS
CX 529	Phone call re Initial contact, 1/15/97	SP002821	Schering-Plough
CX 530	Phone Call re Initial contact, 1/15/97	SP002819	Schering-Plough
CX 531	Phone Call re Follow Up, 1/20/97	SP002820	Schering-Plough
CX 532	<i>Internal Memo</i> , Subject: Kos' plans to send a new Confidentiality Agreement to Schering, per Niaspan- Kogan-Baldini-Jaharis conversations; to Dan Bell (Kos); from Mukesh Patel (Kos); 1/22/97.	AAA0000038	KOS
CX 533	Phone call re Anything from Baldini, 1/22/97	SP002817	Schering-Plough
CX 534	IMS World R&D Focus	SP002822 - 002823	Schering-Plough

KOS CONTINUED

Exhibit No.	Document Description	Document No.	Source
CX 535	Phone call re Extent of our interest?, 1/22/97	SP002818	Schering-Plough
CX 536	<i>Letter and attached Confidentiality Agreement</i> , Subject: Niaspan CDA to Schering; to Karin Gast; from Mukesh Patel (Kos); 1/30/97.	AAA0000045 - 0000047	KOS
CX 537	Project Information	SP002666	Schering-Plough
CX 538	E-mail re Niacin SR and KOS, 2/10/97	SP002814	Schering-Plough
CX 539	Letter re confidential package on Kos' Niaspan product, 2/10/97	SP002813	Schering-Plough
KOS CONTINUED			
CX 540	Letter re Kos' Niaspan, 2/11/97	SP002779 - 002812	Schering-Plough
CX 541	List All Filings Prospectus Rule 424(b)(4), 3/7/97	FTC001212 39113 TcO95 12et627.75 -18.75925 Tc 0 Tw D 0 Tj 6	

Exhibit No.	Document Description	Document No.	Source
CX 546	Memo re Niaspan Opportunity, 3/26/97	SP002770 - 002771	Schering-Plough
CX 547	Handwritten notes, 4/9/97	SP002764 - 002769	Schering-Plough
CX 548	Niaspan Financial Analysis, 4/17/97	SP002737 - 002742	Schering-Plough
KOS CONTINUED			
CX 549	Niaspan Financial Analysis, 4/17/97	SPCID2 1A00049 - 00052	Schering-Plough
CX 550	Ray's Forecast - Base	SP002743 - 002745	Schering-Plough
CX 551	Niaspan Financial Analysis, 4/17/97	SP002731 - 002736	Schering-Plough
CX 552	Handwritten notes, 4/25/97	SP002728 - 002730	Schering-Plough
CX 553	<i>Handwritten notes</i> , Conference Call between Kos and Schering concerning possible Niaspan business venture; taken by Mukesh Patel (Kos); 4/25/97.	AAA0000151 - 0000152	KOS
CX 554	<i>Memo and attached draft proposal</i> , Subject: Niaspan, draft proposal for Schering/Kos deal; to Dave Heatherman (Kos); from Ray Russo; 5/15/97.	AAA0000153 - 0000157	KOS
CX 555	Memo re Niaspan, 5/15/97	SP002723	Schering-Plough
CX 556	<i>Handwritten notes</i> , last conference call between Schering (Gast and Russo) and Kos to discuss Niaspan business venture; recorded by Mukesh Patel (Kos), 5/21/97.	AAA0158	KOS
CX 557	Phone call re Conference call, 5/21/97	SP002721 - 002722	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
KOS CONTINUED			
CX 558	Memo re KOS' Niaspan, 6/9/97	SP002719 - 002720	Schering-Plough
CX 559	Phone call re Status?, 7/15/97	SP002718	Schering-Plough
CX 560	Project Information	SP020706	Schering-Plough
CX 561	Memo re Niacin SR - Discussion guide for use with HMO Formulary decision makers, 8/22/94	SPCID2 1A00102 - 00106	Schering-Plough
CX 562	Hypercholesterolemia focus groups with physicians; Discussion Guide	SPCID2 1A00098 - 00100	Schering-Plough
CX 563	Memo re review of the Niaspan NDA Integrated Summary, 6/30/94	SP002849 - 002863	Schering-Plough
CX 564	Memo re Kos generic ISMN, 6/16/98	SP002986	Schering-Plough
CX 565	Sustained-released Niacin	SP002824	Schering-Plough
CX 566	KOS/Upsher-Smith agreements, 2/7/97; and letter Bell to Troup, 1/27/97, to settle KOS/Upsher-Smith patent issues	USL11367 - 11418	Upsher-Smith
KOS CONTINUED			
CX 567	Letter, Subject: Terms of possible Niaspan license agreement; to Ian Troup; from Daniel Bell (Kos); 1/31/97.	AAA0000346 - 0000347	KOS
CX 568	Letter re License Agreement with KOS , 2/7/97	Upsher-Smith-FTC-145284 - 145304	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 569	<i>Letter</i> , "Re: License Agreement dated February 7, 1997 between Kos ...and Upsher-Smith"; 7/11/97.	AAA0000378 - 0000379	KOS
CX 570	<i>Letter</i> , Subject: Patent stance in Kos-Upsher license agreement; to Rodney Bell (Holland & Knight); cc: Paul Kralovec; from Cecil Schmidt (Merchant & Gould); 7/22/97.	AAA0000380	KOS
CX 571	<i>Letter</i> , Subject: Acrimony regarding patent issues; to Ian Troup, cc: Paul Kralovec; from Dan Bell (Kos); 7/24/97.	AAA0000381	KOS
CX 572	<i>Letter</i> , Subject: Niaspan license agreement- patent issues, to Dan Bell (Kos); from Ian Troup; 7/30/97.	AAA0000382 - 0000383	KOS
CX 573	<i>Letter</i> , Subject: patent "boundaries" in Niaspan license agreement; to Ian Troup; from Dan Bell (Kos); 8/11/97.	AAA0000384	KOS
CX 574	Letter re Our ref: M&G 1866J09-US-LA, 8/19/97	USL09122 - 09123	Upsher-Smith
CX 575	Letter re C.V. Business development Subcommittee Meeting (May 13, 1997)	SP020724 - 020725a	Schering-Plough
CX 576	A Qualitative Evaluation Of The Opportunity For Niaspan In Multiple Lipid Disorders Telephone Interviews With Lipid Specialists (4/97)	SP020707 - 020723	Schering-Plough
CX 577	Phone Call re Niaspan, niacin, 3/13/97	SPCID2 1A00109 - 00110	Schering-Plough

KOS CONTINUED

CX 578-592 **RESERVED**

FDA

CX 593	Letter re petition requesting the FDA to amend regulation controlling the effective approval dates of certain Abbreviated New Drug Applications, 3/3/97	FTC0022341 - 0022360	FDA
CX 594	Letter re Info of developments in implementation of the Drug Price and Patent Term Restoration Act of 1984, 7/29/88	FTC0022361 - 0022366	FDA

Exhibit No.	Document Description	Document No.	Source
CX 595	Letter re 180-day exclusivity provisions from FDA, 6/18/97	FTC 0021577 - 0021579	FDA
CX 596	Granotec, Inc. v. Health and Human Services, et al., Order (Zantac), 7/10/97	FTC 0021585 - 0021586	FTC
CX 597	Abbreviated new Drug Application Regulations; Patent and Exclusivity Provisions; Final Rule, 10/3/94	FTC0022367 - 0022370	FTC
CX 598	Guidance for Industry Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act, 3/00	FTC0021770 - 0021777	FTC
CX 599	General Docket US Court of Appeals for the DC Circuit filings, 3/26/97	FTC0021778 - 0021779	FTC
CX 600	F-D-C reports Prescription Pharmaceuticals and Biotechnology, 1/20/97	FTC0021780 - 0021781	FTC
CX 601	F-D-C reports Prescription Pharmaceuticals and Biotechnology, 5/26/97	FTC0021689 - 0021690	FTC
CX602	Letter to Lipha Pharmaceuticals from Douglas Sporn re approval for Ranitidine Tabs USP, 150 mg and 300mg, 6/17/97	FTC0021735 - 0021739	FTC
CX 603	The Wall Street Journal NOVOPHARM LTD.: Generic version of Zantac is to be sold in US, 7/7/97	FTC0021788	The Wall Street Journal
CX 604	The Wall Street Journal FDA Ruling Snarls Race to Introduce Generic Ulcer Drug, 6/23/97	FTC0021785	The Wall Street Journal
CX 605	F-D-C reports Prescription Pharmaceuticals and Biotechnology, 6/23/97	FTC0021786 - 0021787	FTC
CX 606	The Wall Street Journal NOVOPHARM LTD.: Generic version of Zantac is postponed, 7/10/97	FTC0021784	The Wall Street Journal

Exhibit No.	Document Description	Document No.	Source
CX 607	Federal Register Rules and Regulations, 11/28/97	FTC0021789 - 0021790	FTC
CX 608	Federal Register Rules and Regulations, 11/5/98	FTC0021791 - 0021793	FTC
CX 609	Letter to Upsher-Smith from FDA re abbreviated new drug application for Klor-Con M20, 11/24/98	USL07699 - 07700 FTC0021594 - 0021595	Upsher- Smith
CX610	Memo to Ian Troup from Mark Robbins re November Scientific Affairs Monthly Report, 12/2/98	USL16419 FTC0032591	Upsher- Smith
CX 611	Letter to Upsher-Smith from FDA re abbreviated new drug application for Klor-Con M20, 1/28/99		

Exhibit No.	Document Description	Document No.	Source
CX 620	Memo re Mova and Granutec Decisions, 4/24/98	SP002632 - 002635	Schering-Plough
CX 621	Memo re ANDA Exclusivity, 8/6/99	USL08785 - 08788	Upsher-Smith
CX 622	Klor-Con M Team Meeting, 10/14/99	Upsher-Smith-FTC-088473 - 088507	Upsher-Smith
CX 623	Letter to Upsher-Smith from Douglas Sporn re 11/20/98 approval for Klor-Con M20	Upsher-Smith-FTC- 123129 - 123130	Upsher-Smith
CX 633	Letter to Czaban and Levitt from Jaffe re request for amendment of ANDA, 3/3/97	FTC0021740 - 0021759	FTC
CX 634	Letter to all NDA and ANDA Holders and applicants from FDA, 7/29/88	FTC0021760 - 0021765	FTC
CX 635	Federal register, ANDA; Patent Exclusivity provisions; Final Rule, 10/3/94	FTC0021766 - 0021769	FTC
CX 636	F-D-C reports, 5/26/97	FTC0021782 - 0021783	FTC
CX 636-645	RESERVED		
RESPONDENTS' WHITE PAPERS AND EXPERT REPORTS			
CX 646	Response to Specs 1-10, undated		

Exhibit No.	Document Description	Document No.	Source
CX 653	Memo to R. Baldini, M. Driscoll from S. Linqvist re 1995 Key Monthly Sales Forecast, 6/7/95	SP018321 - 018365	Schering-Plough
CX 654	Memo to Greg Birch from Joann Androconis re Product Performance, 5/22/95	SP018366 - 018382	Schering-Plough
CX 655	1995 Key Plus Plan Discussion, 5/23/95	SP018383 - 018398	Schering-Plough
CX 656			

Exhibit No.	Document Description	Document No.	Source
CX 666	Memo to Ray Russo from Steve Keogh re 1994 Major Account Sales and Rebate Figures for Imdur, K-Dur, Nitro-Dur, Lotrisone, Normodyne, and Vanceril, 6/15/95	SP018536 - 018560	Schering-Plough
CX 667	Key Pharmaceuticals Prescription Report for April 1995	SP018571 - 018598	Schering-Plough
CX 668	Memo to Distribution from Greg Novello re Pipeline Data graphs April 1995, 5/22/95	SP018599 - 018619	Schering-Plough
CX 669	Key K-DUR Data from 2/94 through 1/95	SP018620 - 018659	Schering-Plough
CX 670	E-mail to D'ambrosio and Weintraub from Dan Valerio re Potassium Chloride labeling, 6/12/01	SP018660	Schering-Plough
CX 671	New Product Launch Procedure, Potassium Chloride Tablets, Launch date 9/4/01, 5/30/01 - Valerio	SP018661 - 018662	Schering-Plough
CX 672	Potassium Chloride/K-Dur Tabs, 12 Month Forecast, \$/Units, 5/9/01	SP018663	Schering-Plough
CX 673	Potassium Chloride/K-Dur Tabs, 12 Month Forecast, \$/Units, 5/3/00	SP018664 - 018672	Schering-Plough
CX 674	Schering-Plough, Package design/Component RIC Request, Potassium Chloride Tabs, Effective date 3/15/96, date received 1/16/96	SP018673 - 018677	Schering-Plough
CX 675	Potassium Chloride, USP Extended Release Tabs, Label - Warrick, 2/00	SP018678 - 018681	Schering-Plough
CX 676	Shipment of Potassium Chloride, USP Extended Release Tabs Labels to Paxton Advertising from Schering, 2/16/00	SP018682 - 018686	Schering-Plough
CX 677	E-mail to Dan Valerio from Linda Dytrych re Potassium Chloride, 2/7/00	SP018687 - 018693	Schering-Plough
CX 678	Packaging Approval Routing List for Potassium Chloride Tabs, 1/30/96	SP018694 - 018700	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 679	Package Component Specification for LBL PS ROL Potassium CH TB 10 MEQ 100, RIC No. 18983907, Schering Labs, 6/27/96	SP018701 - 018704	Schering-Plough
CX 680	E-mail from Richard Pipala to Raman kapur re Generic K-Dur, 2/4/00	SP018705	Schering-Plough
CX 681	K-Dur, 20 MEQ only not 10 MEQ, Warrick is user, 3/16/98	SP018706 - 018713	Schering-Plough
CX 682	Risk Authorization, Warrick K-Dur, 3/27/97 - Kapur	SP018714 - 018718	Schering-Plough
CX 683	Letter to R. Pipala from L. Manfredi re Warrick Contingency Plan for Potassium Chloride ER Tabs, 2/26/97	SP018719 - 018721	Schering-Plough
CX 684	K-Dur Potassium Chloride Tabs, Warrick 12 Month Forecast, 2/26/97	SP018722 - 018723	Schering-Plough
CX 685	Standard Costs, K-Dur Potassium Chloride Tabs, Warrick 12 Month Forecast, 2/26/97	SP018724 - 018730	Schering-Plough
CX 686	Chris DiLascia, K-Dur notes, 2/25/97	SP018731 - 018732	Schering-Plough
CX 687			

Exhibit No.	Document Description	Document No.	Source
CX 691	License Agreement between Hercon Labs Corp. and Key Pharmaceuticals, Inc., 3/13/00	SP018766 - 018779	Schering-

Exhibit No.	Document Description	Document No.	Source
CX 704	E-mail to Gilda Clayton from Richard Chipkin re Proposal on co-marketing of Qvar and Airmir from Dainippon, 1/2/01	SP060174 - 060178	Schering-Plough
CX 705	Memo from John Lund to Profit Performance Team re PPT Meeting, 7/18/97, 7/11/97	USL00937 - 00963	Upsher-Smith
CX 706	Meeting Notes from the timeline meeting for Klor-Con M20 on 4/29/97	USL06734 - 06735	Upsher-Smith
CX 707	Letter to Ian Troup from Michael Dey re discussion of possible business arrangement for generic version of K-Dur 20 mEq, 8/14/96	USL08682 - 08683	Upsher-Smith
CX 708	Economic Analysis of the Key/ESI Patent Settlement, Carl Shapiro, 3/20/	FTC0022213 - 0022223	Key
CX 709	Respondent Schering's Statement of the case involving Schering and Upsher-Smith,	FTC0022201 - 0022212	Schering
CX 710	Upsher-Smith's responses to Complaint Counsel's First Set of Interrogatories, 10/22/01	FTC0020535 - 0020548	Upsher-Smith
CX 711	Upsher-Smith's objections and response to FTC CID issued 8/18/00	Upsher-Smith 0000774 - 0000786	Upsher-Smith
CX 712	Upsher-Smith's objections and response to FTC CID issued 8/18/00, 9/29/00	Upsher-Smith 0000794 - 0000893	Upsher-Smith
CX 713	Final Clinical/Statistical Report, Niacor-SR/Niacin, 4/21/97	Upsher-Smith-FTC- 102865 - 102967	Upsher-Smith
CX 714	Protocol Synthesis for Niacor-SR/Fluvastation study, 6/12/97	SP16 00059 - 00060	Schering-Plough
CX 715	Schering's supplemental response to complain counsel's first set of interrogatories, 12/7/01	FTC0021837 - 0021862	FTC
CX 716	Infringement Opinion Regarding U.S. Patent No. 5,397,574 (Assigned to Andrx Pharm., Inc.); Opinion Letter, 7/3/97	USLP0164 - 0174	
CX 715-736	RESERVED		

COMPLAINT COUNSEL'S EXPERTS

Exhibit No.	Document Description	Document No.	Source
CX 737	Hatch-Waxman Act	FTC0021620 - 0021641	FTC
CX 738	Memo to Troup and Evenstad re Pierre Fabre Presentation-6/3/97, 6/12/97	USL13187	Upsher-Smith
CX 739	Klor-Con M20, 7/97	USL06751	Upsher-Smith
CX 740	K-Dur 20, Key Pharmaceuticals, a division of Schering Plough	USL06759	Upsher-Smith
CX 741	Market assumptions re Klor-Con and K-Dur, Dolan	USL06784	Upsher-Smith
CX 742	Assumptions regarding M20	USL07073 - 07075	Upsher-Smith
CX 743	Dolan, 20 mEq assumptions for the projections, 4/30/97	USL08541 - 08544	Upsher-Smith
CX 744	Potassium Chloride (20mEq) Market Forecast recap	AHP13 00029	AHP
CX 745	Letter to Anthony Herman from Paul Heller re information on ESI's projections for settlement discussion, 9/24/97	AHP13 00008 - 00009	AHP
CX 746	Memo to DiLascia from Androconis re K-Dur marketing research backgrounder, 7/1/96	SP23 00369 - 00394	Schering-Plough
CX 747	1998 K-Dur Marketing Plan, DiLascia, 8/1/97	SP23 00087 - 00110	Schering-Plough
CX 748	Pharmaceutical Operations Sales, 1997-2001, 6/5/97	SP23 00307 - 00315	Schering-Plough
CX 749	Marketing Strategies/Action Plan for K-Dur	SP23 00010 - 00011	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 767	“Schering-Plough, Merck Forge Pact,” Yahoo.com, 5/23/00; “Drug Makers Pair Up to Fight Key Patent Losses,” 5/24/00	FTC0015009	FTC
CX 768	Schering-Plough, Merck forge pact to develop new drugs, 5/24	FTC0015010	FTC
CX 769	<i>Handwritten notes</i> , meeting between Schering and Kos to discuss possible Niaspan business venture; recorded by Mukesh Patel (Kos); 4/9/97.	AAA0150	KOS
CX 770	Company Report, 9/22/97	SP13 00849 - 00854	Schering-Plough
CX 771	Letter to Pettit re Secrecy agreement for Niacor-SR, 2/28/97	USL11496 - 11498	Upsher-Smith
CX 772	Fax to JAn Crawford from Pettit re Niacor-SR, 3/3/97	USL11499	Upsher-Smith
CX 773	Letter to Pettit re amendments of agreement, 3/4/97	USL11500	Upsher-Smith
CX 774	Fax to O’Neil from Pettit re licensing considerations, 5/22/97	USL11561 - 11567	Upsher-Smith
CX 775	Memo to Troup from Halvorsen re Pierre Fabre Presentation-6/3/97, 6/11/97	USL11810 - 11811	Upsher-Smith
CX 776	“The Kos is clear; experiences cholesterol marketing warriors flocking to Kos”, Jerry Treppel, 7/1/97	USL11868	Upsher-Smith
CX 777	Upsher’s presentation to TCF	USL12391 - 12394	Upsher-Smith
CX 778	Niacin Franchise; Niacor-SR, 7/97	USL15530 - 15537	Upsher-Smith
CX 779	Fax to Oliver LeFevre from O’Neil re Niacor-SR info, 11/25/97	USL21232 - 21238	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 780	Memo to Kapur from Audibert re Upsher Smith Update, 8/21/97	SP16 00236	Schering- Plough
CX 781			

Exhibit No.	Document Description	Document No.	Source
CX 794	White Papers of Upsher-Smith	FTC0022077 - 0022158	Upsher-Smith
CX 795	R. Diccio Expert Report Revised Exhibit 3, Valuation of Upsher-Smith/SP License (\$ in millions)	FTC0021870 - 0021873	FTC
CX 796	Letter to Vickie O'Neil from Desiree Malanga, re: executed confidentiality agreements, 1) Warrick & Upsher, 2) Schering & Upsher, 4/20/98	SP12 00005 FTC0021874	Schering-Plough FTC
CX 797	Memo to IND #37,984, Niacor-SR from Harvey Arbit and Dianne Gibbs, re: Minutes of FDA Meeting 6/24/92, 7/8/92	Upsher-Smith-FTC- 095050 - 095055	Upsher-Smith
CX 798	Expert Report of Zola Horovitz, Horovitz EX. 1, 10/8/01	FTC0021880 - 0021907	FTC
CX 799	Expert Report of Walter Bratic, Bratic EX. 1, 10/8/01	FTC0021908 - 0021956	FTC
CX 800	Expert Report of Richard DiCicco, DiCicco EX. 3, 10/8/01	FTC0021957 - 0021968	FTC
CX 801	Expert Report of Kenneth McVey, McVey EX. 1, 10/8/01	FTC0021969 - 0021999	FTC
CX 802	Memo of Schering to the FTC, re: file 9910256, 3/23/01	FTC0020549 - 0020600	
CX 803-833	RESERVED		
SEARCH FOR EUROPEAN PARTNER THROUGH MORETON			
CX 834	Letter re Identifying a Niacor-SR European partner, 11/18/96	USL11047 - 11061	Upsher-Smith
CX 835	Letter re Assignment Letter, 1/10/96	USL11336 - 11356	Upsher-Smith
CX 836	Letter re change to the "Product Summary" section, 1/13/97	USL11357 - 11358	Upsher-Smith
CX 837	Preliminary Information Memo; DRAFT	USL11359 - 11365	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 838	Upsher's Confidential Disclosure Niacor-SR	Upsher-Smith-FTC-094106 - 094136	Upsher-Smith
CX 839	Upsher's Niacor-SR Contact Summary, 2/3/97	USL09120 - 09121	Upsher-Smith
CX 840	Fax re Visit to Europe, 4/21/97	USL11510 - 11512	Upsher-Smith
CX 841	Upsher's Niacor-SR Contact Summary, 4/21/97	USL13148 - 13150	Upsher-Smith
CX 842	UPSHER-SMITH Labs Niacor-SR Contact Summary Updated 4/14/97	USL11501 - 11503	Upsher-Smith
CX 843	Upsher's Niacor-SR Contact Summary, date illegible	USL11507 - 11509	Upsher-Smith
CX 844	Fax re Schering declining opportunity for new lipid lowering product, 2/4/97	USL09099 - 09100	Upsher-Smith
CX 845	Fax re Possible corporate partnership with Upsher, Niacor-SR, 2/4/97	USL09102	Upsher-Smith
CX 846	Letter re Niacor-SR rejection, 1/21/97	USL09110	Upsher-Smith
CX 847	Letter re Niacor-SR rejection, 1/21/97	USL09111	Upsher-Smith
CX 848	Fax re New European Licensing Opportunity-Niacor SR, 1/27/97	USL09107	Upsher-Smith
CX 849	Letter re New European Licensing Opportunity-Niacor SR, 1/22/97	USL09113	Upsher-Smith
CX 850	Fax re Niacor-SR rejection, 2/28/97	USL09089	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 851	Fax re Niacor-SR rejection, 2/3/97	USL09118	Upsher-Smith
CX 852	Fax re Niacor-SR rejection, 2/3/97	USL09117	Upsher-Smith
CX 853	Fax re Niacor-SR rejection, 1/31/97	USL09097	Upsher-Smith
CX 854	Fax re Niacor-SR rejection, 2/28/97	USL09090	Upsher-Smith
CX 855	Fax re Niacor-SR rejection, 2/7/97	USL09115	Upsher-Smith
CX 856	Letter re Niacor-SR rejection, 4/9/97	USL09086 - 09088	Upsher-Smith
CX 857	Fax re Niacor-SR rejection, 3/4/97	USL09091	Upsher-Smith
CX 858	Letter re Niacor-SR rejection, 2/3/97	USL09119	Upsher-Smith
CX 859	Fax re Niacor-SR rejection, 2/3/97	USL09104	Upsher-Smith
CX 860	Fax re Niacor-SR rejection, 1/22/97	USL09114	Upsher-Smith
CX 861	Letter re Niacor-SR rejection, 1/22/97	USL09096	Upsher-Smith
CX 862	Letter re Niacor-SR rejection, 2/25/97	USL09092	Upsher-Smith
CX 863	Letter re Niacor-SR rejection, 2/7/97	USL09116	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 864	Fax re Niacor-SR rejection, 2/4/97	USL09098	Upsher-Smith
CX 865	Letter re Niacor-SR rejection, 2/4/97	USL09103	Upsher-Smith
CX 866	Fax re Possible partnership, 6/6/97	USL11803 - 11804	Upsher-Smith
CX 867	Fax re Nicotinic acid, 6/26/97	USL11865 - 11866	Upsher-Smith
CX 868	Memo re Esteve S.A. Presentation, 6/11/97	USL11812 - 11814	Upsher-Smith
CX 869	Letter to Vickie O'Neil from Joan Miro re Niacor-SR rejection, 9/29/97	USL11968	Upsher-Smith
CX 870	Fax to Vickie O'Neil from David Pettit re Pierre Fabre, Servier, and Dr. Esteve confirmed, 5/19/97	USL11559	Upsher-Smith
CX 871	Fax to Moreton from David Colpman re Niacor rejection, 3/13/97	Moreton0000477	Moreton
CX 872	Fax to David Petit from Manfred Foersch re Niacor rejection, 2/14/97	Moreton0000384	Moreton
CX 873	Fax to Moreton from Guy Vercauteren re Niacor opportunity, 2/5/97	Moreton0000385	Moreton
CX 874	Fax to David Petit from Ulf Ljungberg re Niacor rejection, 2/6/97	Moreton0000377	Moreton
CX 875	Fax to David Pettit from Gustav Trilsbach re Niacor rejection, 1/22/97	USL09108	Upsher-Smith
CX 876	Fax to Moreton from Baumann and Kluge re Niacor rejection, 1/22/97	USL09109	Upsher-Smith
CX 877	Fax to Moreton from Harenberg re Niacor rejection, 1/21/97	USL09105	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 878	Letter to David Pettit from Carine Himsworth re Niacor rejection, 1/21/97	USL09106	Upsher-Smith
CX 879	Business Cards	FTC0020180 - 0020186	FTC
CX 880	Memo re Lacer, S.A. Presentation - 6/5/97, 6/12/97	USL11827 - 11829	Upsher-Smith
CX 881	Memo re Pierre Fabre Presentation - 6/3/97, 6/11/97	USL11825 - 11826	Upsher-Smith
CX 882	Fax re presentation on Pierre Fabre organization, 2/6/97	Moreton0000308	Moreton
CX 883	Memo re Servier Presentation - 6/6/97, 6/11/97	USL11808 - 11809	Upsher-Smith
CX 884	Memo re Lacer, S.A. Presentation - 6/5/97, 6/12/97	USL11832 - 11864	Upsher-Smith
CX 885	Niacor-SR overhead presentation, 5/28/97	USL11575 - 11650	Upsher-Smith
CX 886	Upsher-Smith presentation to Searle, 5/28/97	Upsher-Smith-FTC-190621 - 190683	Upsher-Smith
CX 887	Protocol Number 920115-D, 4/30/96	SP16 00141 - 00225	Schering-Plough
CX 888	Fax to O'Neil from Pettit re Contact list w/responses, 1/28/97	Moreton0000165 - 0000167	Moreton
CX 889-898	RESERVED		
EARLY TRIAL INFORMATION			
CX 899	Adverse Reactions to Niacor-SR	Upsher-Smith-FTC-1003760 - 1003763	Upsher-Smith
CX 890	ClinTrials Research-Upsher-Smith Labs Meeting Notes, Study 920115, 5/12/95	Upsher-Smith-FTC-093255 - 093259	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 891	Fax re Discussion points , 10/22/96	Upsher-Smith-FTC-006179 - 006181	Upsher-Smith
CX 892	Data from Niacor SR protocol 920115	Upsher-Smith-FTC-004818 - 004983	Upsher-Smith
CX 893	Niacor SR overhead presentation	USL11712 - 11796	Upsher-Smith
CX 894	Fax from Anita Rackham to Harvey Arbit re Notes from FDA meeting 6/24/92, 6/25/92	Upsher-Smith-FTC-090141 - 090143	Upsher-Smith
CX 895	Letter to Enid Galliera from Harvey Arbit re request for meeting about Niacor-SR, 5/29/92	Upsher-Smith-FTC-090190 - 090191	Upsher-Smith
CX 896			

Exhibit No.	Document Description	Document No.	Source
CX 904-913	RESERVED		
	ADDITIONAL PK STUDY		
CX 914	Meeting Objectives -Upsher, 2/5/97	Upsher-Smith-FTC-107460 - 107463	Upsher-Smith
CX 915	Memo re January Clinical, Regulatory Affairs, and Quality Assurance Monthly Report, 2/5/97	Upsher-Smith-FTC-153541	Upsher-Smith
CX 916	Fax re Clinical Pharmacology and Biopharmaceutics Review, Niacor-SR, 3/26/97	Upsher-Smith-FTC-107456 - 107457	Upsher-Smith
CX 917	Letter re IND 37,984 - Niacor-SR Informational Amendment: Clinical, Minutes from 2/5/97 Meeting regarding Pharmokinetics Issues and Request for Comment regarding Pharmacokinetics Study Protocol Serial Submission No. 088, 2/24/97	Upsher-Smith-FTC-107426 - 107455	Upsher-Smith
CX 918	Upsher's 7/17/97 Meeting Minutes with FDA regarding Niacor-SR, IND #37,984	Upsher-Smith-FTC-1033928 - 1033932	Upsher-Smith
CX 919-928	RESERVED		
	MARKET REPORT		
CX 929	Upsher-SmithNiacor-SR Tablets (ExtenSe 9n5 0 TD 0.1208 Tc 0 Tw (Upsher-) Tj 0 31-9453.41i1E0.ea6KOO8n967 5i 7/0		

Exhibit No.	Document Description	Document No.	Source
CX 961	Memo re Niacor SR Plan Rev. 002, 3/27/97	Upsher-Smith-FTC-113325 - 113339	Upsher-Smith
CX 962	Niacor SR, 2/12/98	USL13251 - 13271	Upsher-Smith
CX 963	Kravolec Product Update 12/1/94 - 2/12/98	USL12577 - 12620	Upsher-Smith
CX 964	Niacor SR 8/14/97	USL09701 - 09875	Upsher-Smith
CX 965	1998 Project Planning Schedule	USL12820 - 12822	Upsher-Smith
CX 966-975	RESERVED		
NIACOR LABELING			
CX 976	Niacor-SR package insert	Upsher-Smith-FTC-1003778 - 1003797	Upsher-Smith
CX 977	Memo re Niacor-SR Annotated Package Insert, 6/4/97	Upsher-Smith-FTC-077106 - 077126	Upsher-Smith
CX 978	Memo re Niacor-SR Labeling: Footnote Table IV, 6/19/97	Upsher-Smith-FTC-077105	Upsher-Smith
CX 979	Memo re Niacor-SR Annotated Package Insert, 6/21/97	FTC0022321 - 0022340	Upsher-Smith
CX 980	Niaspan Clinical Data Rev. 8/97	Upsher-Smith-FTC-1033909 - 1033913	Upsher-Smith
CX 981-990	RESERVED		
MARKET RESEARCH			

Exhibit No.	Document Description	Document No.	Source
CX 991	Management of Hypercholesterolemia: Teleconference with Cardiologists and Primary Care Physicians, 10/96	USL12977 - 13002	Upsher-Smith
CX 992	Current Practices and the Role of Niacin in the management of High Cholesterol: Teleconference with Primary Care Physicians, 2/97	USL12904 - 12923	Upsher-Smith
CX 993-1017	RESERVED		
REPORTS ON CLINICAL STUDIES			
CX 1018	Protocol 920115 Final Clinical/Statistical Report, 12/5/97	Upsher-Smith-FTC-003492.01 - 003854	Upsher-Smith
CX 1019	Final Study Report of Protocol 920944, 5/13/98	Upsher-Smith-FTC-175676 - 175796	Upsher-Smith
CX 1020	Fax to Marge Garske from Claude Drobnes re Table of Patients with Notable Elevations in ALT or AST, Text Table 45, 10/31/97	Upsher-Smith-FTC-175976 - 175979	Upsher-Smith
CX 1021	Niacor-SR Protocol 920115 Safety Analysis- Introduction	Upsher-Smith-FTC-190689 - 190705	Upsher-Smith
CX 1022	Niacor-SR product description	USL11651 - 11711	Upsher-Smith
CX 1023	Niacor-SR product description	Upsher-Smith-FTC-094137 - 094199	Upsher-Smith
CX 1024	Physicians Desk Reference, PDR 55 th Edition, 2001	FTC 0021271 - 0021275	KOS
CX 1025	Goodman & Gilman's The Pharmacological Basis of Therapeutics, ninth edition, McGraw Hill-Health Professions Division	FTC 0021276 - 0021279	FTC
CX 1026-1040	RESERVED		
SCHERING EVALUATION OF NIACOR			
CX 1041	Memo Kapur to Audibert, Lauda transmitting Upsher confidentiality agreement for Niacor, 4/15/98	SP05 00026 - 00028	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX 1042	Niacor Information	SP16 00061 - 00112	Schering-Plough
CX 1043	Protocol Synopsis, Draft	SP16 00113 - 00140	Schering-Plough
CX 1044	Memo re Niacin, 6/17/97	SP16 00040 - 00047	Schering-Plough
CX 1045	Sales/Net from Niacor SR, Audibert to Kapur, 6/17/97	SP16 00231 - 00235	Schering-Plough
CX 1046			

Exhibit No.	Document Description	Document No.	Source
CX 1074	Memo re Updated Forecast-Upsher-Smith Products, 6/19/97	SP17 00001 - 00002	Schering-Plough
CX 1075	Fax re Schering Purchase requisition, 9/18/97	USL21254 - 21255	Upsher-Smith
CX 1076	Letter from Vickie O'Neil to Bill Hisey re possible deal with IVAX Corp., 6/19/98	Upsher-Smith-FTC-1028254 - 1028255	Upsher-Smith
CX 1077-1086	RESERVED		
POST AGREEMENT			
CX 1087	Memo Kapur to Lauda, Cesan; project leader should brief on niacin Kapur for Troupe meetings, 7/2/97	SP16 00237	Schering-Plough
CX 1088	Letter re confirmation that Upsher has suspended all research on Niacor-SR, 10/6/98	SP05 00004 - 00011	Schering-Plough
CX 1089	KOS Pharmaceuticals, Competitive Intelligence from IPO Docs, 8/1/97	USL13213 - 13214	Upsher-Smith
CX 1090	Memo re Niacor-SR, 8/12/97	Upsher-Smith-FTC-149892 - 149894	Upsher-Smith
CX 1091	Memo re Niacor-SR, 8/12/97	USL11937 - 11939	Upsher-Smith
CX 1092	Letter re protocols on Niacor, 8/21/97	SP002936 - 002940	Schering-Plough
CX 1093	Niacor-SR Urine PK Study	USL12363	Upsher-Smith
CX 1094	Nicor-SR, 9/22/97	USL11934 - 11936	Upsher-Smith

Exhibit No.	Document Description	Document No.	Source
CX 1095	Niacor-SR Strategy meeting, 9/23/97	USL11946 - 11951	Upsher-Smith
CX 1096	Niacor-SR NDA Approval Strategy	USL13228 - 13239	Upsher-Smith
CX 1097	Nicor SR NDA approval strategy, 9/23/97	Upsher-Smith-FTC-153369 - 153392	Upsher-Smith
CX 1098	Memo re October Clinical, Regulatory Affairs, and Quality Assurance Monthly Report, 11/5/97	Upsher-Smith-FTC-153513	Upsher-Smith
CX 1099	Faxes Kapur to Audibert (11/7/97) and Kapur to Troupe (10/21/97) re delayed clinical data on Niacor-SR	SP05 00013 - 00014	Schering-Plough
CX 1100	Upsher 1998 Marketing Plans	USL16064 - 16158	Upsher-Smith
CX 1101	Correspondence from Paul Thompson to Troup re amendment agreement, 6/30/97	USL02008 - 02023	Upsher-Smith
CX 1102	Correspondence from Troup to Kapur re Royalty payment due to Upsher-Smith, 6/11/98	USL03221	Upsher-Smith
CX 1103	Correspondence from Troup to Kapur re modifications that need to be made to the amendment agreement, 7/29/97	USL11879 - 11911	Upsher-Smith
CX 1104			

Exhibit No.

Document Description

Document No.

Source

Exhibit No.	Document Description	Document No.	Source
CX 1147	Schering Press Release-“Schering -Plough and Centocor announce international licensing agreement for Avakine Monoclonal Antibody”, 4/6/98	FTC0021867 - 0021869	Schering-Plough
CX 1148	E-mail re couter proposal from Interardia on Bextra, 4/1/99	SP060360 - 060361	Schering-Plough
CX 1149	Memo re Fournier’s Lipidil (fenofibrate), 3/18/96	SP018835 - 018839	Schering-Plough
CX 1150			

Exhibit No.	Document Description	Document No.	Source
CX 1160	Follow-up question on Zelman	SP051051 - 051057	Schering-Plough
CX 1161	Memo re Zelman Update, 7/5/00	SP051072 - 051074	Schering-Plough
CX 1162	Fax re Zelman, 7/25/00	SP050934 - 050937	Schering-Plough
CX 1163	Letter re Schering's interest in deal with Novartis on Zelman, 7/26/00	SP050908 - 050911	Schering-Plough
CX 1164	Summary of Olmesartan/Olmesartan HCTZ Co-promotion Proposed Agreement for discussion	SP059722	Schering-Plough
CX 1165	Memo re ICOS's Pafase, 1/29/01	SP053707 - 053712	Schering-Plough
CX 1166	E-mail re Pafase, 3/20/01	SP053697	Schering-Plough
CX 1167	Schering's Press release - "Schering-Plough and RIBI Immunochem Announce Distribution Agreement for Melacine Melanoma Vaccine", 3/16/98	FTC0021865 - 0021866	Schering-Plough
CX 1168	E-mail re Vapreotide, 1/17/00	SP049686	Schering-Plough
CX 1169	Schering's Press release - "Schering-Plough in Agreement with Zonagen for Worldwide Marketing Rights to Vasomax for Treatments of Male Erectile Dysfunction", 11/17/97	FTC0021863 - 0021864	Schering-Plough
CX 1170	Proposal to create a partnership with Merck and Company to develop and market cholesterol-lowering and allergy products, 2/14/00	SP021470 - 021546	Schering-Plough
CX 1171	Analysis of Product Alliances, transmittal 9/21/99	SP021547 - 021662	Schering-Plough
CX 1172	Ezetimibe, 7/01	SP040991 - 041020	Schering-Plough

Exhibit No.

Exhibit No.

Document Description

Document No.

Source

Exhibit No.	Document Description	Document No.	Source
CX	Protein DESIgn Labs & Boehringer Mannheim, agreements include equity investment, product licensing and joint manufacturing, press release, 10/29/93	FTC0009182 - 0009184	FTC
CX	Parke-Davis & Pfizer recap analysis, 3/96	FTC0009190 - 0009202	FTC
CX	deCODE Genetics 10-K filing, 12/31/00	FTC0009238 - 0009239	FTC
CX	Affymax & Wyeth-Ayerst recap analysis, 2/94	FTC0009317 - 0009325	FTC
CX	Regeneron & Proctor and Gamble 10-K filing, 12/31/98	FTC0009360 - 0009361	FTC
CX	Warner-Lambert sells Parke-Davis facility and certain brand products to King Pharmaceuticals, press release, 3/2/98	FTC0009405 - 0009407	FTC
CX	Scios and Genetech Auriculin for acute renal failure, press release, 1/31/95	FTC0009483 - 0009485	FTC
CX	Scios and Genetech Auriculin for acute renal failure, press release, 5/29/96	FTC0009481 - 0009482	FTC
CX	GenVec and Parke-Davis recap analysis, 7/97	FTC0009493 - 0009500	FTC
CX	Alexion and Proctor & Gamble recap analysis, 1/99	FTC0009554 - 0009566	FTC
CX	Alexion and Proctor & Gamble C5 inhibitor for CPB, press release, 10/24/01	FTC0009690	FTC
CX	Millennium & Lilly Genes for atherosclerosis & cancer, press release, 10/24/95	FTC0009711 - 0009713	FTC
CX	Millennium & Lilly Genes to include select areas of oncology, press release, 4/15/96	FTC0009708	FTC
CX	Cardiome Pharma and Hoffmann-La Roche recap summary, 5/98, rev. 6/99	FTC0009714	FTC
CX	Nortran Pharmaceuticals and Hoffman-La Roche Atrial arrhythmia compounds, press release, 5/7/98	FTC0009716 - 0009717	FTC
CX	Axys Pharmaceuticals and Rhone-Poulenc Rorer, Protease inhibitors associated with inflammatory diseases, 12/18/98	FTC0009773 - 0009774	FTC
CX	Texas Biotechnology and SmithKline Beecham form alliance to market and develop Novastan IN North America, 8/6/97	FTC0009871 - 0009872	FTC

Exhibit No.	Document Description	Document No.	Source
CX	Bristol-Myers Squibb and ICAGEN Initiate Ion Channel Collaboration; Alliance to focus on small molecules for atrial fibrillation, press release, 9/30/97	FTC0009877	FTC
CX	GelTex and Sankyo Pharmaceutical recap summary, 11/99, rev. 12/99	FTC0009881	FTC
CX	GelTex Pharmaceuticals and Sankyo sign letter of intent for licensing agreement for GelTex's chloesterol-lowering products, press release, 11/15/99	FTC0009914 - 0009915	FTC
CX	Interneuron licenses North American rights for Ceraxon to Takeda Chemical Industries, Inc., press release, 12/2/99	FTC0009977 - 0009979	FTC
CX	Cytel and Schwartz Pharma recap summary, 5/95	FTC0009981 - 0009993	FTC
CX	Scios and Wyeth-Ayerst recap summary, 10/96	FTC0009996	FTC
CX	Scios and Wyeth-Ayerst Trafermin for stroke and cardio, press release, 10/23/96	FTC0009997 - 0009998	FTC
CX	Gensia Pharmaceuticals and Boehringer Mannheim Geomatrix nifedipine for hypertension, press release, 10/11/94	FTC0008129 - 0008130	FTC
CX	3-Dimensional Pharmaceuticals and Wyeth-Ayerst, stock purchase agreement, 6/97	FTC0008133 - 0008156	FTC
CX	3-Dimensional Pharmaceuticals and Wyeth-Ayerst, Orally active thrombin inhibitors, press		

Exhibit No.	Document Description	Document No.	Source
CX	Memo to Enters and Dr. Spicehandler from Dr. Chatterjee, re SPRI Review of Frovatriptan, 6/18/98	SP050155 - 050161	Schering-Plough
CX	E-mail to Poorvin from Rubino re Zelmec Deal Analysis: Novartis Perspective, 7/25/00	SP050926 - 050928	Schering-Plough
CX	Fax to Poorvin from Sundar Kodiyalam, re Zelmec Update, 7/21/00	SP050954 - 050970	Schering-Plough
CX	Memo to Raul Cesan from Poorvin, re Levovin (ICN), 5/10/01	SP053672 - 053673	Schering-Plough
CX	E-mail to Roehl and Estol from Chipkin, re Genentech PAC document/BD Section, 8/2/00	SP058833 - 058836	Schering-Plough
CX	E-mail to Roehl, Reisinger, Cuffie-Jackson, and Grint from Chipkin, re Genetech's hul 1124, 4/7/00	SP058887 - 058888	Schering-Plough
CX	Memo to Spicehandler and Enters from Roehl, re Licensing opportunity: hul1124-Genetech's monoclonal antibody for psoriasis, 3/27/00	SP058894 - 058896	Schering-Plough
CX	Atherogenics, AGI-1067; license, 10/22/99	SP066009 - 066011	Schering-Plough
CX	Alkermes (formerly Enzytech), injectable delivery system for Alpha Interferon; development/license, 2/10/92, amended 7/26/95	SP066007 - 066008a	Schering-Plough
CX			

Exhibit No.	Document Description	Document No.	Source
CX	Cephalon, Alzheimer's drug; collaboration/research, 5/23/90	SP066024 - 066028	Schering-Plough
CX	Chiroscience, asthma drug; collaboration/research, 6/24/97	SP066029 - 066030	Schering-Plough
CX	Chugai Pharmaceuticals, Psoriasis drug; license, 3/2/98	SP066031 - 066032	Schering-Plough
CX	COR Therapeutics, Integrelin; collaboration, 4/10/95	SP066033 - 066038	Schering-Plough
CX	Corvas, Hepatitis C inhibitor; collaboration/license, 6/11/97	SP066039 - 066040	Schering-Plough
CX	Endorecherche, Antiestrogen & antiandrogen; development/license	SP066041 - 066043	Schering-Plough
CX	Enzon, PEG intron-A; development/license/supply, 11/14/90, amended 2/23/92 and 6/30/95	SP066044 - 066046	Schering-Plough
CX	Genome Therapeutics Corp., Genomic fungal infection treatment; collaboration/license, 9/23/97	SP066047 - 066048	Schering-Plough
CX	Genome Therapeutics Corp., Asthma product; development/license, 12/20/96	SP066049 - 066051	Schering-Plough
CX	Genome Therapeutics Corp., Any disease-treatment product developed from GTC databases (?); collaboration/license, 12/7/95	SP066052 - 066054	Schering-Plough
CX	Human Genome Sciences, Access to HGS genome technology; R&D collaboration/license, 6/28/96	SP066055 - 066062	Schering-Plough
CX	ICN, Ribavirin; license, 7/28/95	SP066063 - 066068	Schering-Plough
CX	Incyte (Synteni), Access to Incyte's microarray technology & databases; collaboration/license, 10/1/98	SP066069 - 066071	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX	Medi-ject & Becton Dickinson, Needle-free injectors, syringes, & adopters; license/supple, 1/20/98	SP066072 - 066073	Schering-Plough
CX	Myriad Genetics, "all products"; research collaboration/license, 4/22/97	SP066074 - 066077	Schering-Plough
CX	Neurogen, any product containing Program Dopamine Agonist/Antagonist technology; collaboration/license, 7/27/95	SP066078 - 066082	Schering-Plough
CX	Novopharm, all ANDA approved products, for eight years after 5/11/95; (Warrick) distribution, 5/2/94, amended 5/11/95	SP066107 - 066109	Schering-Plough
CX	Novopharm Biotech., genetic biotechnology pharm. products from "Option Substances"; development/manufacture/marketing/supply/distribution, 2/17/97	SP066110 - 066112	Schering-Plough
CX	Orion, Toremifene tablet; supply/distribution, 3/14/95	SP066083 - 066084	Schering-Plough
CX	Ribi ImmunoChem Research, Melacine; distribution/supply, 3/14/95	SP066085 - 066086	Schering-Plough
CX	SciClone, Thymosin Alpha-1 (TA-1); license/development/supply, 1/12/93	SP066087 - 066090	Schering-Plough
CX	Sennes, SDI gene & protein patent sublicense, 8/18/99	SP066091 - 066093	Schering-Plough
CX	Sepracor, DCL (loratadine metabolite); license, 12/5/97	SP066094	Schering-Plough
CX	Sequus Pharma., Caelyx/Doxil; supply/distribution, 8/29/96	SP066095 - 066098	Schering-Plough
CX	TerraGen Diversity, bacteria extract; research collaboration/license	SP066099 - 066100	Schering-Plough
CX	Transgene, S.A., use of Transgene's adenovirus gene therapy & delivery systems; research collaboration/license/option, 2/2/98	SP066101 - 066102	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX	Univ. of Toronto, Alzheimer's gene therapy; development/lincene, 12/9/96	SP066103 - 066106	Schering-Plough
CX	Memo to Enter from Chipkin re Confidential Material from Geltex, 3/23/99	SP003086	Schering-Plough
CX	Memo to Thompson from Maetzold re Background inof on Cholesterol market for cholestagel analysis, 4/28/99	SP003190 - 003195	Schering-Plough
CX	E-mail to Audibert, Lauda, Poorvin, Chipkin, Veltri, Ress, and Mackey from Derek Maetzold, re Geltex Acquisition Paper, 6/4/99	SP003171 - 003189	Schering-Plough
CX	Memo to Enters from Audibert re Geltex, 6/24/99	SP003078	Schering-Plough
CX	Fax to Audibert from Collins re Updated financial model runs for Gel-Tex , 6/5/99	SP003201 - 003207	Schering-Plough
CX	Fax to Audibert from Collins re Modified Geltex model-Scenario 3C, 8/18/99	SP003208 - 003211	Schering-Plough
CX	Memo to Chipkin from Maetzold re Cholestagel Forecast, 5/5/99	SP003196 - 003197	Schering-Plough
CX	Memo to Lauda from Maetzold, re Cholestagel Forecast	SP003198 - 003200	Schering-Plough
CX	Cholestagel, P&L forecast w/assumptions, notes and additional figures, 5/99	SP003065 - 003070	Schering-Plough
CX	Draft, Acquisition of Geltex	SP003071 - 003077	Schering-Plough
CX	Memo to Enters and Spicehandler from Chatterjee re SPRI Technical Assessment of Cholestagel from GelTex Pharmaceuticals, Inc., 9/1/99	SP003226 - 003236	Schering-Plough
CX	Atherogenics, Inc., Initial Presentation, 4/15/98	SPCID2 1B 00001 - 00050	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX	Atherogenics AGI-1067 presentation documents, 9/28/98	SPCID 1B 00051 - 000116	Schering-Plough
CX	AGI-1067 Indication	SP067042 - 067061	Schering-Plough
CX	Letter to Karin Gast from Mitchell Glass re 6/9/98 request for follow-up on AGI-1067, 6/24/98	SPCID2 1B 00209 - 00210	Schering-Plough
CX	Memo to Rudy Ress from Karin Gast re Answers from AtherGenics, 10/16/98	SPCID2 1B 00149 - 00201	Schering-Plough
CX	Letter to Shutts from Andrews re Due Diligence–AtheroGenics, 12/4/98	SPCID2 1B 00322 - 00323	Schering-Plough
CX	AGI-1067 Development total Allocated Costs	SPCID2 1B 00299 - 00302	Schering-Plough
CX	Memo to Roehl from Reif re AtheroGenics AGI-1067 Review, 12/10/98	SPCID 1B 00328 - 00331	Schering-Plough
CX	Pre-clinical pharmacology review of AGI-1067/DD visit Report, 12/23/98	SPCID2 1B 00305 - 00307	Schering-Plough
CX	Memo to Roehl from Halliwell re Due deligence review of AtheroGenics AGI 1067 In-Licensing Review, 1/6/99	SPCID2 1B 00308 - 00313	Schering-Plough
CX	Memo to Roehl from Lipka re Atherogenics AGI-1067 Review, 1/26/99	SPCID2 1B 00314 - 00321	Schering-Plough
CX	Memo to Roehl from Kosoglou re Clinical Pharmacology Due Dilligence Review, 5/26/99	SPCID2 1B 00297 - 00298	Schering-Plough
CX	Template for project manhour estimates:harw2(CX) Tj 52 - 067061	SPCID2 1B 00308 - 00313	Plough Schefing-

Exhibit No.	Document Description	Document No.	Source
CX	AGI-1067: Athergenic's anti-restenosis compound PRB briefing document, Meeting: 7/26/99	SPCID2 1B 00339 - 00390	Schering-Plough
CX	AGI-1067, A Licensing Opportunity for the Prevention of Restenosis from Atherogenics, 9/13/99 presented to SPOC	SPCID2 1B 00391 - 00496	Schering-Plough
CX	Memo to Distribution from Qaalfa Dibeethi re Vasomax docs, 4/13/97	SP088425 - 088484	Schering-Plough
CX	Fax to Poorvin from Dourado re "vase case" comparison with Viagra, 9/30/97	SP088347 - 088348	Schering-Plough
CX	Memo to Dourado and Hurtado from Koorie and Melas re Commercial Assessment of Invicorp & Vasomax, , 8/21/97	SP089135 - 089156	Schering-Plough
CX	Memo to Dourado and Rubino from Schafroth re Licensing opportunities: Vasomax, OD fltamide, 3/4/97	SP089157 - 089170	Schering-Plough
CX	Memo to Baron, Hurato, and Poorvin from Schultz re Zonagen, 6/10/97	SP089174	Schering-Plough
CX	Memo to Chatterjee from Schultz re Vasomax, 7/9/97	SP079927	Schering-Plough
CX	E-mail to Schultz and Melas from Estok re Vasomax product profile, 8/27/97	SP088590 - 088591	Schering-Plough
CX	Letter to Richard Lorber from John Potthof re safety tabs related to adverse experiences in Zonagen, 10/2/97	SP085732	Schering-Plough
CX	Letter to Schultz from Bowman re updatd adverse advent tabs on ZON 200, 10/24/97	SP087640	Schering-Plough
CX	E-mail to Schultz from Lorber re Zonagen clinical and regulartory inof on vasomax, 9/9/97	SP088592 - 088594	Schering-Plough
CX	Memo to Distribution from Crosby re Vasomax: Draft PRB/SPOC document for review, 10/6/97	SP088780 - 088923	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX	Memo to Distribution from Lorber re Vasomax Assessment, 8/27/97	SP088386 - 088389	Schering-Plough
CX	Memo to Chatterjee from Haenick re Vasomax Tabs - Zonagen, Inc., 9/10/97	SP088595 - 088598	Schering-Plough
CX	Memo to Cesan from Jensen and Chatterjee re Vasomax: Status of issues and SPRI position, 11/7/97	SP089019 - 089023	Schering-Plough
CX	Memo to Enters from Lauda re Due diligence of Zonagen's Vasomax, 8/20/97	SP089133	Schering-Plough
CX	Fax to Schultz from Kelli Marks, re Minutes and action items from 10/2 meeting, 10/2/97	SP088536 - 088538	Schering-Plough
CX	Memo to Farrell and Weiner from Estok, re Vasomax licensing opportunity trademark evaluation, 10/13/97	SP088606 - 088607	Schering-Plough
CX	Memo to Chatterjee, Haenick, Halliwell, and Rinaldi from Bette Schultz re: Vasomax chronic tox, 9/23/97	SP088549 - 088561	Schering-Plough
CX	Letter to Craig McCarthy from Isidoro Perez re: request review of Vasomax Marketing Authorization Application in U.K., 10/22/97	SP088562	Schering-Plough
CX	Memo to Bowman from DeSousa re Vasomax international regulatory strategy, 10/13/97	SP088563 - 088564	Schering-Plough
CX	Memo to Distribution from Enters re ad hoc PRB Meeting, 10/9/97	SP088122 - 088293	Schering-Plough
CX	memo to meeting Attendees from Enters re Minutes, ad hoc PRB Meeting 10/10/97, 10/20/97	SP088940 - 088954	Schering-Plough
CX	Memo to Collins from Schultz re Vasomax SPOC presentation, 10/13/97	SP088486 - 088516	Schering-Plough
CX	Fax to Bill Silbey from Bette Schultz re Vasomax board paper, 10/20/97	SP088975 - 088983	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX	Clinical Development Summary, 6/98	SPCID2 1D 12257 - 12379	Schering-Plough
CX	Marimastat Presentation	SPCID2 1D 12518 - 12601	Schering-Plough
CX	Memo to Hurado and Schultz from Wael Fayad, re Marimastat U.S. commercial assessment, 9/22/98	SPCID2 1D 12652 - 12671	Schering-Plough
CX	Marimastat Matrix Metalloproteinase Inhibitor, British Biotech, marketing assessment, 11/11/98	SPCID2 1D 12722 - 12753	Schering-Plough
CX	Letter to Chatterjee from Peter Brown reply to 12/10/98 SPRI request for data, 12/16/98	SPCID2 1D 09820 - 09822	Schering-Plough
CX	Fax to Schultz and Chatterjee from Peter Brown, reply to questions raised in fax of 3/8/99, 3/16/99	SPCID2 1D 09807 - 09817	Schering-Plough
CX	Earnings Impact assessment, 7/23/99	SPCID2 1D 11403 - 11405	Schering-Plough
CX	Letter to Poorvin from Schultz re financial analysis, 7/22/99	SPCID2 1D 11406 - 11426	Schering-Plough
CX	Draft P&L review	SPCID2 1D 11376	Schering-Plough
CX	Preliminary P&L analysis	SPCID2 1D 11388 - 11389	Schering-Plough
CX	Memo to Enters and Spicehandler from Chatterjee re SPRI Assessment of Marimastat, 12/1/98	SPCID2 1D 12799 - 12852	Schering-Plough
CX	Letter to Chatterjee from Peter Brown re "boxes for tech review", 4/16/99	SPCID2 1D 09805 - 09806	Schering-Plough
CX	Marimastat, Alicensing opportunity for a novel late-stage anticancer agent from British Biotech, for presentation to PRB 6/25/99	SPCID2 1D 10062 - 10223	Schering-Plough

Exhibit No.	Document Description	Document No.	Source
CX	Marimastat, Alicensing opportunity for a novel late-stage anticancer agent from British Biotech, for presentation to SPOC 6/28/99	SPCID2 1D 09854 - 10061	Schering-Plough
CX	Development, license and supply agreement between Schering Corp., Schering-Plough LTD. and R.P. Scherer Corp., 3/24/99	SPCID00001 - 00089	Schering-Plough
CX	Exclusive license and supply agreement between Becton Dickinson and Co. and Schering Corp., 5/15/99	SPCID00090 - 00137	Schering-Plough
CX	Development, License and Supply Agreement between Schering Corp. and Enzon, Inc., 10/29/90	SPCID00138 - 00249	Schering-Plough
CX	Exclusive License Agreement between Atherogenics, Inc. and Schering Corp., 10/25/99	SPCID00442 - 00517	Schering-Plough
CX	Agreement between British Biotech Pharmaceuticals LTD. and Schering Corp., 9/6/99	SPCID00254 - 00391	Schering-Plough
CX	Option Agreement between Schering Corp. and Silicon Microdevices, Inc., 12/18/98	SPCID00695 - 00726	Schering-Plough
CX	Collaboration and license agreement between Pharmacopeia, Inc. and Schering Corp., 10/29/98	SPCID00631 - 00694	Schering-Plough
CX	Letter to Kade Kadrie from Joe Wardell re Status of Niacor-SR Licensing Effort, 9/16/93	USL09883 - 09884	Upsher-Smith
CX	Memo to Distribution from Bob Coleman re Niacor-SR, changes in the marketplace that may significantly impact the potential marketability of the Niacor-SR product, 8/12/97	USL11931 - 11361	Upsher-Smith
CX			

Exhibit No.	Document Description	Document No.	Source
CX	Letter to Tara Koslov from John Niels re Other Schering deals, 3/29/01	FTC0001400 - 0001404 Schering-Plough White Paper Exhibits 0000203 - 0000207	Schering- Plough
CX	Plaintiff's Statement Pursuant to Rule 12G, Key v. Upsher-Smith, 1/10/97		